Revlimid Wave 3 Tracking Survey; Trends in Usage in Multiple Myeloma and myelodysplastic syndrome - A Survey of Fifty One Oncologists and Hematologists - Market Research Reports

Welcome - Home - Register - Login - Help/FAQ - 0 items

Search
Enter keywords, a title or
a report id number below.

Advanced


	Select a currency for use throughout the site

Viewing report

Order by Fax
Printer Friendly
Send to Friend
Enquire before Buying

Electronic

Revlimid Wave 3 Tracking Survey; Trends in Usage in Multiple Myeloma and myelodysplastic syndrome - A Survey of Fifty One Oncologists and Hematologists
Panel Intelligence, LLC, Dec 2007


	Description



		Products Mentioned



		Enquire before Buying



		Send to a Friend

Study Description

Topic
- Revlimid

Respondent Type
- Oncology/Hematology

Specialty
- Medical Oncology (n = 5), Hematology/Oncology (n = 46)

Region
- United States only

Methodology
- Online survey, self-administered via a Panel Intelligence website
- Duration: 30 minutes
- Size: 51 respondents
- Fielding dates: November 28 to December 2, 2007

Objectives: To periodically track changes in usage of Revlimid by surveying a set of Oncologists and Hematologists regarding their current and future practices in treatment of patient with multiple myeloma (MM) and myelodysplastic syndrome (MDS).

Specifically to:

- Determine the current market share held by Revlimid and other medications for MDS/MM patients.
- Evaluate Revlimid based on physician and patient opinions.
- Anticipate the future use and changes from current use of Revlimid.
- Reveal side effects and cost issues Revlimid patients experience.

Inclusion Criteria and Respondent Demographics:

- Board-certified or eligible Oncologist or Hematologist
- In practice between 2 and 30 years
- Spends at least 75% of professional time in clinical practice
- Have prescribed Revlimid for at least 10 MM and/or MDS patients

Top of page